@lilianimariee's GLP-1 transformation claims, fact-checked

A nurse on TikTok shows off dramatic weight loss results she attributes to GLP-1 medication, calling herself "unrecognizable." While these drugs do produce substantial weight loss, personal transformation videos often skip the clinical context people need.

What does this video actually claim?

@lilianimariee shows before and after photos suggesting major weight loss while promoting Eden, a telehealth platform that prescribes GLP-1 medications like semaglutide and tirzepatide. She uses hashtags connecting her transformation to the "GLP-1 community."

The video doesn't specify which medication she used, the timeframe, or her starting weight. This matters because GLP-1 outcomes vary significantly based on these factors.

Her "unrecognizable" claim fits a common pattern where social media users attribute dramatic changes to GLP-1s without discussing the full picture of what these medications actually do.

Do GLP-1 medications really cause this kind of weight loss?

Yes, but the data is more nuanced than dramatic before-and-after posts suggest. The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% average body weight loss with 2.4mg semaglutide over 68 weeks.

For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed even better results. Participants lost 20.9% of body weight on average with the 15mg dose over 72 weeks.

These are averages, though. Individual results ranged from minimal weight loss to over 25% body weight reduction. The clinical trials also combined medication with lifestyle counseling, which many social media posts don't mention.

What's missing from this kind of content?

Personal transformation videos rarely discuss side effects, which affected most trial participants. In STEP 1, 74% experienced gastrointestinal issues including nausea, diarrhea, and vomiting.

The timeframe matters too. Meaningful weight loss with GLP-1s typically takes 4-6 months, with peak effects around 16-20 weeks. Quick transformations aren't realistic expectations.

Cost is another blind spot. These medications run $800-1,500 monthly without insurance coverage. Many patients can't sustain treatment long-term, and weight regain often follows discontinuation.

Is promoting telehealth GLP-1 services problematic?

Not necessarily, but it depends on the medical oversight. Legitimate telehealth platforms require comprehensive health assessments and ongoing monitoring by licensed providers.

The FDA has approved semaglutide 2.4mg (Wegovy) and tirzepatide up to 15mg (Zepbound) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related conditions.

However, social media promotion can create unrealistic expectations. GLP-1s work best as part of comprehensive care including dietary counseling and regular medical follow-up, not as standalone solutions promoted through transformation posts.

What should you actually know about GLP-1s?

These medications represent genuine advances in obesity treatment, but they're not magic bullets. The STEP and SURMOUNT trials showed consistent, clinically meaningful weight loss when combined with lifestyle interventions.

Proper candidates have BMI ≥30 or ≥27 with conditions like type 2 diabetes or hypertension. Starting doses begin low (0.25mg weekly for semaglutide) and increase gradually over months to minimize side effects.

Most importantly, these are chronic treatments. Weight regain typically occurs if you stop taking them, making long-term planning essential before starting.